Sickle Cell Anemia Therapeutics Industry Research Report 2024

Sickle Cell Anemia Therapeutics Industry Research Report 2024


Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Highlights

The global Sickle Cell Anemia Therapeutics market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.
Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.
In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Sickle Cell Anemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Anemia Therapeutics.
The Sickle Cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sickle Cell Anemia Therapeutics market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sickle Cell Anemia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals

Product Type Insights

Global markets are presented by Sickle Cell Anemia Therapeutics type, along with growth forecasts through 2030. Estimates on revenue are based on the price in the supply chain at which the Sickle Cell Anemia Therapeutics are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Sickle Cell Anemia Therapeutics segment by Type

Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Sickle Cell Anemia Therapeutics market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Sickle Cell Anemia Therapeutics market.
Sickle Cell Anemia Therapeutics Segment by Application
Child
Adult

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Sickle Cell Anemia Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Anemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Sickle Cell Anemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Sickle Cell Anemia Therapeutics industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Anemia Therapeutics.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Sickle Cell Anemia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Sickle Cell Anemia Therapeutics by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
1.2.2 Blood Transfusion
1.2.3 Pharmacotherapy
1.2.4 Bone Marrow Transplant
2.3 Sickle Cell Anemia Therapeutics by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Child
2.3.3 Adult
2.4 Assumptions and Limitations
3 Sickle Cell Anemia Therapeutics Breakdown Data by Type
3.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Type (2019-2024)
3.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2025-2030)
4 Sickle Cell Anemia Therapeutics Breakdown Data by Application
4.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Application (2019-2024)
4.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2019-2024)
5 Global Growth Trends
5.1 Global Sickle Cell Anemia Therapeutics Market Perspective (2019-2030)
5.2 Global Sickle Cell Anemia Therapeutics Growth Trends by Region
5.2.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Sickle Cell Anemia Therapeutics Historic Market Size by Region (2019-2024)
5.2.3 Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2025-2030)
5.3 Sickle Cell Anemia Therapeutics Market Dynamics
5.3.1 Sickle Cell Anemia Therapeutics Industry Trends
5.3.2 Sickle Cell Anemia Therapeutics Market Drivers
5.3.3 Sickle Cell Anemia Therapeutics Market Challenges
5.3.4 Sickle Cell Anemia Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue
6.1.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue (2019-2024)
6.1.2 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2019-2024)
6.2 Global Sickle Cell Anemia Therapeutics Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Sickle Cell Anemia Therapeutics Head office and Area Served
6.4 Global Sickle Cell Anemia Therapeutics Players, Product Type & Application
6.5 Global Sickle Cell Anemia Therapeutics Players, Date of Enter into This Industry
6.6 Global Sickle Cell Anemia Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Sickle Cell Anemia Therapeutics Market Size (2019-2030)
7.2 North America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
7.4 North America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Sickle Cell Anemia Therapeutics Market Size (2019-2030)
8.2 Europe Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
8.4 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size (2019-2030)
9.2 Asia-Pacific Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
9.4 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Sickle Cell Anemia Therapeutics Market Size (2019-2030)
10.2 Latin America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
10.4 Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size (2019-2030)
11.2 Middle East & Africa Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
11.4 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Emmaus Medical
11.1.1 Emmaus Medical Company Detail
11.1.2 Emmaus Medical Business Overview
11.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Introduction
11.1.4 Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.1.5 Emmaus Medical Recent Development
11.2 Addmedica
11.2.1 Addmedica Company Detail
11.2.2 Addmedica Business Overview
11.2.3 Addmedica Sickle Cell Anemia Therapeutics Introduction
11.2.4 Addmedica Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.2.5 Addmedica Recent Development
11.3 Gamida Cell
11.3.1 Gamida Cell Company Detail
11.3.2 Gamida Cell Business Overview
11.3.3 Gamida Cell Sickle Cell Anemia Therapeutics Introduction
11.3.4 Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.3.5 Gamida Cell Recent Development
11.4 GlycoMimetics
11.4.1 GlycoMimetics Company Detail
11.4.2 GlycoMimetics Business Overview
11.4.3 GlycoMimetics Sickle Cell Anemia Therapeutics Introduction
11.4.4 GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.4.5 GlycoMimetics Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Sickle Cell Anemia Therapeutics Introduction
11.5.4 Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.5.5 Pfizer Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Sickle Cell Anemia Therapeutics Introduction
11.6.4 Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.6.5 Novartis Recent Development
11.7 Global Blood Therapeutics
11.7.1 Global Blood Therapeutics Company Detail
11.7.2 Global Blood Therapeutics Business Overview
11.7.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Introduction
11.7.4 Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.7.5 Global Blood Therapeutics Recent Development
11.8 Micelle BioPharma
11.8.1 Micelle BioPharma Company Detail
11.8.2 Micelle BioPharma Business Overview
11.8.3 Micelle BioPharma Sickle Cell Anemia Therapeutics Introduction
11.8.4 Micelle BioPharma Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.8.5 Micelle BioPharma Recent Development
11.9 Bluebird Bio
11.9.1 Bluebird Bio Company Detail
11.9.2 Bluebird Bio Business Overview
11.9.3 Bluebird Bio Sickle Cell Anemia Therapeutics Introduction
11.9.4 Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.9.5 Bluebird Bio Recent Development
11.10 Prolong Pharmaceuticals
11.10.1 Prolong Pharmaceuticals Company Detail
11.10.2 Prolong Pharmaceuticals Business Overview
11.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction
11.10.4 Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.10.5 Prolong Pharmaceuticals Recent Development
11.11 Modus Therapeutics
11.11.1 Modus Therapeutics Company Detail
11.11.2 Modus Therapeutics Business Overview
11.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Introduction
11.11.4 Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.11.5 Modus Therapeutics Recent Development
11.12 Sangamo Biosciences
11.12.1 Sangamo Biosciences Company Detail
11.12.2 Sangamo Biosciences Business Overview
11.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Introduction
11.12.4 Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.12.5 Sangamo Biosciences Recent Development
11.13 Bioverativ
11.13.1 Bioverativ Company Detail
11.13.2 Bioverativ Business Overview
11.13.3 Bioverativ Sickle Cell Anemia Therapeutics Introduction
11.13.4 Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.13.5 Bioverativ Recent Development
11.14 Imara
11.14.1 Imara Company Detail
11.14.2 Imara Business Overview
11.14.3 Imara Sickle Cell Anemia Therapeutics Introduction
11.14.4 Imara Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.14.5 Imara Recent Development
11.15 Ironwood Pharmaceuticals
11.15.1 Ironwood Pharmaceuticals Company Detail
11.15.2 Ironwood Pharmaceuticals Business Overview
11.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction
11.15.4 Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022)
11.15.5 Ironwood Pharmaceuticals Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 5. Global Sickle Cell Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 6. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2019-2024)
Table 7. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 8. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2025-2030)
Table 9. Global Sickle Cell Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 10. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2019-2024)
Table 11. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 12. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2025-2030)
Table 13. Global Sickle Cell Anemia Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Sickle Cell Anemia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Sickle Cell Anemia Therapeutics Market Share by Region (2019-2024)
Table 16. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Sickle Cell Anemia Therapeutics Market Share by Region (2025-2030)
Table 18. Sickle Cell Anemia Therapeutics Market Trends
Table 19. Sickle Cell Anemia Therapeutics Market Drivers
Table 20. Sickle Cell Anemia Therapeutics Market Challenges
Table 21. Sickle Cell Anemia Therapeutics Market Restraints
Table 22. Global Top Sickle Cell Anemia Therapeutics Manufacturers by Revenue (US$ Million) & (2019-2024)
Table 23. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Manufacturers (2019-2024)
Table 24. Global Sickle Cell Anemia Therapeutics Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 25. Global Key Players of Sickle Cell Anemia Therapeutics, Headquarters and Area Served
Table 26. Global Sickle Cell Anemia Therapeutics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Sickle Cell Anemia Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. North America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 32. North America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 33. Europe Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Asia-Pacific Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 37. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Latin America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 40. Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 41. Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 42. Middle East & Africa Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 43. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Emmaus Medical Company Detail
Table 46. Emmaus Medical Business Overview
Table 47. Emmaus Medical Sickle Cell Anemia Therapeutics Product
Table 48. Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Emmaus Medical Recent Development
Table 50. Addmedica Company Detail
Table 51. Addmedica Business Overview
Table 52. Addmedica Sickle Cell Anemia Therapeutics Product
Table 53. Addmedica Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Addmedica Recent Development
Table 55. Gamida Cell Company Detail
Table 56. Gamida Cell Business Overview
Table 57. Gamida Cell Sickle Cell Anemia Therapeutics Product
Table 58. Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Gamida Cell Recent Development
Table 60. GlycoMimetics Company Detail
Table 61. GlycoMimetics Business Overview
Table 62. GlycoMimetics Sickle Cell Anemia Therapeutics Product
Table 63. GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 64. GlycoMimetics Recent Development
Table 65. Pfizer Company Detail
Table 66. Pfizer Business Overview
Table 67. Pfizer Sickle Cell Anemia Therapeutics Product
Table 68. Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Pfizer Recent Development
Table 70. Novartis Company Detail
Table 71. Novartis Business Overview
Table 72. Novartis Sickle Cell Anemia Therapeutics Product
Table 73. Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Novartis Recent Development
Table 75. Global Blood Therapeutics Company Detail
Table 76. Global Blood Therapeutics Business Overview
Table 77. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product
Table 78. Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Global Blood Therapeutics Recent Development
Table 80. Micelle BioPharma Company Detail
Table 81. Micelle BioPharma Business Overview
Table 82. Micelle BioPharma Sickle Cell Anemia Therapeutics Product
Table 83. Micelle BioPharma Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Micelle BioPharma Recent Development
Table 85. Bluebird Bio Company Detail
Table 86. Bluebird Bio Business Overview
Table 87. Bluebird Bio Sickle Cell Anemia Therapeutics Product
Table 88. Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Bluebird Bio Recent Development
Table 90. Prolong Pharmaceuticals Company Detail
Table 91. Prolong Pharmaceuticals Business Overview
Table 92. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product
Table 93. Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Prolong Pharmaceuticals Recent Development
Table 95. Modus Therapeutics Company Detail
Table 96. Modus Therapeutics Business Overview
Table 97. Modus Therapeutics Sickle Cell Anemia TherapeuticsProduct
Table 98. Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 99. Modus Therapeutics Recent Development
Table 100. Sangamo Biosciences Company Detail
Table 101. Sangamo Biosciences Business Overview
Table 102. Sangamo Biosciences Sickle Cell Anemia TherapeuticsProduct
Table 103. Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Sangamo Biosciences Recent Development
Table 105. Bioverativ Company Detail
Table 106. Bioverativ Business Overview
Table 107. Bioverativ Sickle Cell Anemia TherapeuticsProduct
Table 108. Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 109. Bioverativ Recent Development
Table 110. Imara Company Detail
Table 111. Imara Business Overview
Table 112. Imara Sickle Cell Anemia TherapeuticsProduct
Table 113. Imara Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 114. Imara Recent Development
Table 115. Ironwood Pharmaceuticals Company Detail
Table 116. Ironwood Pharmaceuticals Business Overview
Table 117. Ironwood Pharmaceuticals Sickle Cell Anemia TherapeuticsProduct
Table 118. Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2017-2022) & (US$ Million)
Table 119. Ironwood Pharmaceuticals Recent Development
Table 120. Emmaus Medical Company Information
Table 121. Emmaus Medical Business Overview
Table 122. Emmaus Medical Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 123. Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 124. Emmaus Medical Recent Development
Table 125. Addmedica Company Information
Table 126. Addmedica Business Overview
Table 127. Addmedica Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 128. Addmedica Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 129. Addmedica Recent Development
Table 130. Gamida Cell Company Information
Table 131. Gamida Cell Business Overview
Table 132. Gamida Cell Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 133. Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 134. Gamida Cell Recent Development
Table 135. GlycoMimetics Company Information
Table 136. GlycoMimetics Business Overview
Table 137. GlycoMimetics Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 138. GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 139. GlycoMimetics Recent Development
Table 140. Pfizer Company Information
Table 141. Pfizer Business Overview
Table 142. Pfizer Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 143. Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 144. Pfizer Recent Development
Table 145. Novartis Company Information
Table 146. Novartis Business Overview
Table 147. Novartis Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 148. Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 149. Novartis Recent Development
Table 150. Global Blood Therapeutics Company Information
Table 151. Global Blood Therapeutics Business Overview
Table 152. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 153. Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 154. Global Blood Therapeutics Recent Development
Table 155. Micelle BioPharma Company Information
Table 156. Micelle BioPharma Business Overview
Table 157. Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 158. Micelle BioPharma Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 159. Micelle BioPharma Recent Development
Table 160. Bluebird Bio Company Information
Table 161. Bluebird Bio Business Overview
Table 162. Bluebird Bio Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 163. Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 164. Bluebird Bio Recent Development
Table 165. Prolong Pharmaceuticals Company Information
Table 166. Prolong Pharmaceuticals Business Overview
Table 167. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 168. Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 169. Prolong Pharmaceuticals Recent Development
Table 170. Modus Therapeutics Company Information
Table 171. Modus Therapeutics Business Overview
Table 172. Modus Therapeutics Sickle Cell Anemia TherapeuticsRevenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 173. Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 174. Modus Therapeutics Recent Development
Table 175. Sangamo Biosciences Company Information
Table 176. Sangamo Biosciences Business Overview
Table 177. Sangamo Biosciences Sickle Cell Anemia TherapeuticsRevenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 178. Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 179. Sangamo Biosciences Recent Development
Table 180. Bioverativ Company Information
Table 181. Bioverativ Business Overview
Table 182. Bioverativ Sickle Cell Anemia TherapeuticsRevenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 183. Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 184. Bioverativ Recent Development
Table 185. Imara Company Information
Table 186. Imara Business Overview
Table 187. Imara Sickle Cell Anemia TherapeuticsRevenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 188. Imara Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio
Table 189. Imara Recent Development
Table 190. Ironwood Pharmaceuticals Company Information
Table 191. Ironwood Pharmaceuticals Business Overview
Table 192. Ironwood Pharmaceuticals Sickle Cell Anemia TherapeuticsRevenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 193. Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million) Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings